Nuclear Medicine And Biology SCIE

國(guó)際簡(jiǎn)稱：NUCL MED BIOL 參考譯名：核醫(yī)學(xué)與生物學(xué)

主要研究方向：醫(yī)學(xué)-核醫(yī)學(xué) 非預(yù)警期刊審稿周期：一般,3-8周約8周

《核醫(yī)學(xué)與生物學(xué)》(Nuclear Medicine And Biology)是一本由Elsevier Inc.出版的以醫(yī)學(xué)-核醫(yī)學(xué)為研究特色的國(guó)際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評(píng)論文章和綜述文章，及時(shí)報(bào)道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預(yù)警名單。

4區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
38 年發(fā)文量
3.6 IF影響因子
未開放 是否OA
82 H-index
1993 創(chuàng)刊年份
Bimonthly 出版周期
Multi-Language 出版語(yǔ)言

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized.

These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.

Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

[ 查看全部 ]

投稿咨詢加急咨詢

Nuclear Medicine And Biology期刊信息

ISSN：0969-8051
出版語(yǔ)言：Multi-Language
是否OA：未開放
E-ISSN：1872-9614
出版地區(qū)：UNITED STATES
是否預(yù)警：否
出版商：Elsevier Inc.
出版周期：Bimonthly
創(chuàng)刊時(shí)間：1993
開源占比：0.1881
Gold OA文章占比：35.59%
OA被引用占比：0.0953...
出版國(guó)人文章占比：0.1
出版撤稿占比：0
研究類文章占比：100.00%

Nuclear Medicine And Biology CiteScore評(píng)價(jià)數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

0.658

0.787

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Radiology, Nuclear Medicine and Imaging	Q1	71 / 333	78%
大類：Medicine 小類：Cancer Research	Q2	107 / 230	53%
大類：Medicine 小類：Molecular Medicine	Q2	89 / 178	50%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個(gè)指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對(duì)2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評(píng)論、會(huì)議論文、書籍章節(jié)和數(shù)據(jù)論文。

Nuclear Medicine And Biology中科院評(píng)價(jià)數(shù)據(jù)

中科院 2023年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學(xué)	4區(qū)

中科院 2022年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學(xué)	4區(qū)

中科院 2021年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學(xué)	4區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學(xué)	4區(qū)

中科院 2021年12月升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學(xué)	4區(qū)

中科院 2020年12月舊的升級(jí)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學(xué)	4區(qū)

Nuclear Medicine And Biology JCR評(píng)價(jià)數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING	SCIE	Q1	36 / 204	82.6%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING	SCIE	Q2	53 / 204	74.26%

Nuclear Medicine And Biology歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Nuclear Medicine And Biology中國(guó)學(xué)者發(fā)文選摘

1、A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo
Author: Yu Tang, Yingjiang Hu, Weihao Liu, Lin Chen, Yan Zhao, Huan Ma, Jijun Yang, Yuanyou Yang, Jiali Liao, Jiming Cai, Yue Chen, Ning Liu

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2019, Vol.70, 23-31, DOI:10.1016/j.nucmedbio.2019.01.007
2、In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model
Author: Honglei Jiao, Xinming Zhao, Jiahui Liu, Tuo Ma, Zhaoqi Zhang, Jingmian Zhang, Jianfang Wang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2018, Vol., , DOI:10.1016/j.nucmedbio.2018.11.004
3、Radiosynthesis and biological evaluation of N-(2-[18F]fluoropropionyl)-3,4-dihydroxy-l-phenylalanine as a PET tracer for oncologic imaging
Author: Caihua Tang, Dahong Nie, Ganghua Tang, Siyuan Gao, Shaoyu Liu, Fuhua Wen, Xiaolan Tang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.50, 39-46, DOI:10.1016/j.nucmedbio.2017.04.002
4、99mTc-3PRGD2 scintigraphy to stage liver fibrosis and evaluate reversal after fibrotic stimulus withdrawn
Author: Xin Zhang, Qiyong Guo, Yu Shi, Weina Xu, Shupeng Yu, Zhiguang Yang, Li Cao, Changping Liu, Zhoushe Zhao, Jun Xin

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.49, 44-49, DOI:10.1016/j.nucmedbio.2017.02.004
5、Simple and rapid radiosynthesis of N-18F-labeled glutamic acid as a hepatocellular carcinoma PET tracer
Author: Aixia Sun, Shaoyu Liu, Xiaolan Tang, Dahong Nie, Ganghua Tang, Zhanwen Zhang, Fuhua Wen, Xiaoyan Wang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.49, 38-43, DOI:10.1016/j.nucmedbio.2017.02.003
6、Effect of methoxy group position on biological properties of 18F–labeled benzyl triphenylphosphonium cations
Author: Shuting Chen, Zuoquan Zhao, Ying Zhang, Wei Fang, Jie Lu, Xianzhong Zhang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.49, 16-23, DOI:10.1016/j.nucmedbio.2017.02.002
7、Gefitinib enhances radiotherapeutic effects of 131I–hEGF targeted to EGFR by increasing tumor uptake of hEGF in tumor xenografts
Author: Lu Xia, He Peng, Luo Zhiqiang, Zhang Xiaoli

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.48, 63-68, DOI:10.1016/j.nucmedbio.2017.01.013
8、99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen
Author: Xiaoping Xu, Jianping Zhang, Silong Hu, Simin He, Xiao Bao, Guang Ma, Jianmin Luo, Jingyi Cheng, Yingjian Zhang

Journal: NUCLEAR MEDICINE AND BIOLOGY, 2017, Vol.48, 69-75, DOI:10.1016/j.nucmedbio.2017.01.010